Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trial

Keyphrases

• Hypertrophic Cardiomyopathy 100%
• Randomized Phase II Trial 100%
• Phase II Trial 100%
• Valsartan 100%
• Disease Progression 40%
• Placebo 40%
• Confidence Interval 20%
• Placebo-controlled 20%
• Heart Failure 20%
• Serum Levels 20%
• Pathogenic Variants 20%
• Myocardial Fibrosis 20%
• Left Ventricular Wall Thickness 20%
• N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) 20%
• Cardiac Function 20%
• Change from Baseline 20%
• Between-group Difference 20%
• Angiotensin Receptor Blockers 20%
• Cardiac Structure 20%
• Left Ventricular Hypertrophy 20%
• Phase II Clinical Trial 20%
• Tissue Doppler 20%
• Disease Evolution 20%
• Peak Systolic Velocity 20%
• Left Atrial Volume 20%
• Safe Medication 20%
• Sarcomeric Genes 20%
• Wall Volume 20%
• Heart Arrhythmia 20%
• High-sensitivity Troponin T 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Hypertrophic Cardiomyopathy 100%
• Valsartan 100%
• Placebo 60%
• Disease Exacerbation 40%
• Clinical Trial 20%
• Congestive Heart Failure 20%
• Heart Arrhythmia 20%
• Disease Course 20%
• Angiotensin Receptor Antagonist 20%
• Heart Left Ventricle Hypertrophy 20%
• Heart Ventricle Hypertrophy 20%
• Troponin T 20%
• Heart Muscle Fibrosis 20%